ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Effect of 2015 T2 Hepatocellular Carcinoma Exception Policy Implementation on Waitlist Time and Tumor Characteristics

C. Durkin1, D. E. Kaplan2, T. Bittermann2

1Internal Medicine, University of Pennsylvania, Philadelphia, PA, 2Gastroenterology, University of Pennsylvania, Philadelphia, PA

Meeting: 2020 American Transplant Congress

Abstract number: A-140

Keywords: Allocation, Hepatocellular carcinoma, Liver transplantation, Waiting lists

Session Information

Session Name: Poster Session A: Liver: Hepatocellular Carcinoma and Other Malignancies

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: A United Network for Organ Sharing (UNOS) policy change in 2015 created a 6-month delay in the receipt of T2 hepatocellular carcinoma (HCC) exception points to require observation of nonaggressive tumor biology and improve the disparity in liver transplant (LT) access for non-HCC candidates. We hypothesized that the policy change has resulted in longer waitlist time and more aggressive bridging locoregional therapy (LRT).

*Methods: Patients transplanted with a first T2 HCC exception application on or after 10/8/2015 (last LT date 3/31/2019; post-policy) were compared to T2 HCC exception LT recipients from 1/1/2010-9/31/2015 (pre-policy) using data from the UNOS. Descriptive statistics were used to compare LT recipients in each group.

*Results: In total, 3,836 pre-policy and 1,644 post-policy LTs were identified. Post-policy LTs had longer wait times from first application to LT (median 259 days [211, 360] vs. 182 [92, 346]; p<0.001), but with significant regional variation (Figure). There was no difference in the proportion of patients who underwent LRT prior to their first exception application (11.6% pre-policy vs. 11.4% post-policy; p=0.9). Pre-policy patients received fewer treatments overall than post-policy LTs (0 LRT: 21 vs. 9.4%; 1 LRT: 53.7 vs. 44.9%; 2 LRTs 18.7 vs. 30.2%; and >3 LRTs 6.6 vs. 15.6%; p<0.001). Among those with >1 application before LT (N=3,998), post-policy patients were less likely to have multiple tumors (7.7% vs. 14.6%; p<0.001) or alpha-fetoprotein >10ng/mL (28.6% vs. 43.4%; p<0.001) and had smaller residual tumor size of their dominant lesion (median 0cm [0, 1.8] vs. 1.4cm [0, 2.2]; p<0.001) at the time of the last application. On explant, there was no significant difference in the number of tumors, largest tumor size or proportion with extra-hepatic involvement between the two groups (p>0.05 for all). Post-policy LTs were more likely to have complete necrosis of all tumors on explant (23.5% vs. 18.3%; p<0.001).

*Conclusions: In nearly half of UNOS regions, the 2015 HCC policy has minimally changed waiting time for these candidates. However, T2 HCC recipients are more likely to receive more aggressive LRT leading up to LT in the post-policy era.

 border=

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Durkin C, Kaplan DE, Bittermann T. Effect of 2015 T2 Hepatocellular Carcinoma Exception Policy Implementation on Waitlist Time and Tumor Characteristics [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/effect-of-2015-t2-hepatocellular-carcinoma-exception-policy-implementation-on-waitlist-time-and-tumor-characteristics/. Accessed June 6, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences